InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (4 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
4
T+90 hit rate
67%
T+90 mean return
-2.0%
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Smith Mark Douglas, Director. Insider active across 3 companies, notably Teladoc Health, Inc.. Cumulatively, 20 disclosures have been logged. Split: 1 buy · 4 sells. Total volume traded: €223k. History available since 8 July 2021. The latest transaction was filed on 15 August 2024 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Declarations20 total
4,000 shares@ US$7.078100.0% of flowCommon StockSEC:0001628280-24-037693:0
Canonical exit: 13 Nov 2024 (T+90)
3,731 shares0Ordinary SharesSEC:0001765581-24-000078:0
7,000 shares@ US$4.7150.0% of flowCommon StockSEC:0001127602-24-020800:0
8,490 shares0Common StockSEC:0001127602-24-019403:0
417 shares@ US$119.2723.2% of flowOrdinary SharesSEC:0001765581-23-000110:0
3,075 shares0Ordinary SharesSEC:0001765581-23-000090:0
6,051 shares0Common StockSEC:0001562180-23-005580:0
7,000 shares@ US$4.7150.0% of flowCommon StockSEC:0001562180-23-003442:0
420 shares@ US$154.680631.4% of flowOrdinary SharesSEC:0001765581-22-000130:0
2,561 shares0Ordinary SharesSEC:0001765581-22-000098:0
7,397 shares0Common StockSEC:0001562180-22-005519:0
819 sharesCommon StockSEC:0001415889-22-005235:0
417 shares@ US$121.300.0003% mcap50.0% of flowOrdinary SharesSEC:0001765581-21-000133:0
417 shares@ US$121.3022.7% of flowOrdinary SharesSEC:0001765581-21-000133
2,246 shares0Ordinary SharesSEC:0001765581-21-000083
2,246 shares0Ordinary SharesSEC:0001765581-21-000083:0
2,605 shares0Common StockSEC:0001562180-21-004894
2,605 shares0Common StockSEC:0001562180-21-004894:0
524 sharesCommon StockSEC:0001179110-21-005495
524 sharesCommon StockSEC:0001179110-21-005495:0
20 of 20 declarations
About Smith Mark Douglas
Mark Douglas Smith is a Director at Teladoc Health, Inc., Phreesia, Inc., and Jazz Pharmaceuticals plc. In these roles, he contributes to the governance and strategy of the companies. His expertise in the healthcare and biotechnology sectors is essential for their development.
